Comparative efficacy evaluation of two modified-live PRRS vaccines against a heterologous PRRSV 1-7-4 challenge

Add to my reading list Remove from my reading list

The use of Ingelvac PRRS® vaccines can significantly reduce lung lesions following challenge with heterologous PRRSV isolates (86-94% ORF5 nucleotide similarity) in the three-week-old pig respiratory challenge model.1 In addition, it has been demonstrated that the implementation of a systematic methodology for PRRS control that utilizes modified-live vaccine for the control of wild type-PRRSV infections can mitigate the consequences of infection on health and performance.2,3 It is necessary for modified-live vaccines to be effective against  heterologous challenge with current PRRSV field isolates. Ingelvac PRRS® MLV demonstrated heterologous protection against challenge with current PRRSV lineage-1 RFLP 1-7-4 and 1-3-4 isolates.4 The objective of this study was to evaluate the efficacy of Ingelvac PRRS® MLV (BIAH-Boehringer Ingelheim Animal Health, Duluth, Georgia) and Prevacent® PRRS  (Elanco Animal Health, Greenfield, Indiana) in a three-week-old pig respiratory challenge model, using a heterologous PRRSV RFLP 1-7-4 field isolate that was isolated from North Carolina in 2016.  

Read the full publication here.